Abstract
Rapid development of genomic studies has led to development of new molecular biomarkers for diagnosis of primary and recurrent forms of bladder cancer. The study objective is to evaluate the current status of molecular biomarkers for diagnosis of recurrence and/or progression of bladder cancer and possibilities of their clinical use. A search of literature published in the last several years in the Pubmed and MedLine databases was performed. The obtained data was analyzed, sensitivity, specificity, positive and negative prognostic value were determined. The requirements for quality and characteristics of molecular biomarkers vary significantly depending on a specific case. The clinical role of urine biomarkers in observation of patients with nonmuscle invasive bladder cancer remains uncertain. Assays approved by the U.S. Food and Drug Administration do not demonstrate desired sensitivity and specificity which leads to their limited use. Currently, commercial assays of urine biomarkers are not sufficiently studied which predetermines further search for the optimal method of early diagnosis of bladder cancer. Multicenter clinical studies will allow to determine the place of each molecular biomarker in clinical practice.
Highlights
Rapid development of genomic studies has led to development of new molecular biomarkers for diagnosis of primary and recurrent forms of bladder cancer
The study objective is to evaluate the current status of molecular biomarkers for diagnosis of recurrence and/or progression of bladder cancer and possibilities of their clinical use
The requirements for quality and characteristics of molecular biomarkers vary significantly depending on a specific case
Summary
ĐŠĐžŃŃĐŸŃĐșĐŸĐżĐžŃ, ĐŸĐ±ŃДпŃĐžĐœŃŃĐ°Ń ĐČ ĐșĐ°ŃĐ”ŃŃĐČĐ” Â«Đ·ĐŸĐ»ĐŸŃĐŸĐłĐŸ ŃŃĐ°ĐœĐŽĐ°ŃŃа» ĐŸĐ±ĐœĐ°ŃŃĐ¶Đ”ĐœĐžŃ Đ ĐĐ, ŃĐČĐ»ŃĐ”ŃŃŃ ĐžĐœĐČĐ°Đ·ĐžĐČĐœĐŸĐč ĐżŃĐŸŃДЎŃŃĐŸĐč, ŃĐŸĐżŃŃĐ¶Đ”ĐœĐœĐŸĐč Ń ŃĐžŃĐșĐŸĐŒ ŃĐ°Đ·ĐČĐžŃĐžŃ ĐžĐœŃĐ”ĐșŃĐžĐŸĐœĐœŃŃ ĐŸŃĐ»ĐŸĐ¶ĐœĐ”ĐœĐžĐč, ĐČ ŃĐŸ ĐČŃĐ”ĐŒŃ ĐșĐ°Đș ŃĐžŃĐŸĐ»ĐŸĐłĐžŃĐ”ŃĐșĐŸĐ” ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžĐ” ĐŒĐŸŃĐž ĐžĐŒĐ”Đ”Ń ĐČŃŃĐŸĐșŃŃ ŃŃĐČŃŃĐČĐžŃДлŃĐœĐŸŃŃŃ (84 %) лОŃŃ ĐżŃĐž ĐŸĐżŃŃ ĐŸĐ»ŃŃ ĐČŃŃĐŸĐșĐŸĐč ŃŃĐ”ĐżĐ”ĐœĐž Đ·Đ»ĐŸĐșĐ°ŃĐ”ŃŃĐČĐ”ĐœĐœĐŸŃŃĐž. ĐĄ ŃŃĐ”ŃĐŸĐŒ ĐœĐžĐ·ĐșĐŸĐč ŃŃĐČŃŃĐČĐžŃДлŃĐœĐŸŃŃĐž ŃĐžŃĐŸĐ»ĐŸĐłĐžŃĐ”ŃĐșĐŸĐłĐŸ ĐžŃŃĐ»Đ”ĐŽĐŸĐČĐ°ĐœĐžŃ ĐŒĐŸŃĐž, Đ° ŃĐ°ĐșжД ĐČŃĐ”ĐŒĐ”ĐœĐœŃŃ Đž ĐžĐœĐŸĐłĐŽĐ° ŃĐžĐœĐ°ĐœŃĐŸĐČŃŃ ĐŸĐłŃĐ°ĐœĐžŃĐ”ĐœĐžĐč, ŃĐČŃĐ·Đ°ĐœĐœŃŃ Ń ĐżŃĐŸĐČĐ”ĐŽĐ”ĐœĐžĐ”ĐŒ ŃĐžŃŃĐŸŃĐșĐŸĐżĐžĐž, бŃлО ŃĐ°Đ·ŃĐ°Đ±ĐŸŃĐ°ĐœŃ Đž ĐČĐœĐ”ĐŽŃĐ”ĐœŃ ĐČ ĐșĐ»ĐžĐœĐžŃĐ”ŃĐșŃŃ ĐżŃĐ°ĐșŃĐžĐșŃ ĐŒĐœĐŸĐłĐŸŃĐžŃĐ»Đ”ĐœĐœŃĐ” Đ±ĐžĐŸĐŒĐ°ŃĐșĐ”ŃŃ ĐČ ĐŒĐŸŃĐ”. ĐŁ ŃŃĐŽĐ° Đ±ĐžĐŸĐŒĐ°ŃĐșĐ”ŃĐŸĐČ, ĐŸĐŽĐŸĐ±ŃĐ”ĐœĐœŃŃ ĐŁĐżŃĐ°ĐČĐ»Đ”ĐœĐžĐ”ĐŒ ĐżĐŸ ŃĐ°ĐœĐžŃĐ°ŃĐœĐŸĐŒŃ ĐœĐ°ĐŽĐ·ĐŸŃŃ Đ·Đ° ĐșĐ°ŃĐ”ŃŃĐČĐŸĐŒ пОŃĐ”ĐČŃŃ ĐżŃĐŸĐŽŃĐșŃĐŸĐČ Đž ĐŒĐ”ĐŽĐžĐșĐ°ĐŒĐ”ĐœŃĐŸĐČ ĐĄĐšĐ, ĐœĐ” ĐŸĐżŃĐ”ĐŽĐ”Đ»Đ”ĐœĐ° ŃŃĐ”ĐżĐ”ĐœŃ ĐșĐ»ĐžĐœĐžŃĐ”ŃĐșĐŸĐč Đ·ĐœĐ°ŃĐžĐŒĐŸŃŃĐž, ŃŃĐŸ ĐŸĐłŃĐ°ĐœĐžŃĐžĐČĐ°Đ”Ń ĐžŃ ĐžŃĐżĐŸĐ»ŃĐ·ĐŸĐČĐ°ĐœĐžĐ”, ĐŸŃĐŸĐ±Đ”ĐœĐœĐŸ ĐżŃĐž ĐœĐ°Đ±Đ»ŃĐŽĐ”ĐœĐžĐž Đ·Đ° паŃĐžĐ”ĐœŃĐ°ĐŒĐž Ń ŃĐžŃĐșĐŸĐŒ ĐżŃĐŸĐłŃĐ”ŃŃĐžŃĐŸĐČĐ°ĐœĐžŃ Đž / ОлО ŃĐ”ŃОЎОĐČĐ° Đ ĐĐ [4].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have